ADARGA LIMITED
Company number 09742902 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Score: D (Weak – Requires Intensive Care)
Adarga Limited is in a fragile financial condition. While the company has managed to stem the worst of its cash bleed and has secured vital shareholder support, it remains deeply loss-making, carries a severe negative equity position, and is entirely dependent on external financing to continue operating. The business is effectively on life support, with a clear but high-risk recovery plan.
1. Financial Health Score: D (Weak)
Why D?
The company shows some improving vital signs (cash increase, lower losses) but suffers from chronic, severe underlying conditions (massive accumulated losses, negative net worth, negative working capital). Without the committed support of its principal shareholder and a planned fundraising round, the business would likely be insolvent. This is not a terminal diagnosis, but the patient is in the intensive care unit.
2. Key Vital Signs
| Metric | 2025 | 2024 | 2023 | Interpretation |
|---|---|---|---|---|
| Net Assets (Equity) | -£793,768 | -£3,711,668 | +£4,218,028 | Critical deficiency – negative net worth, though improved from 2024. |
| Cash at Bank | £1,142,799 | £176,784 | £3,773,022 | Improved – cash reserves have been replenished, likely from share issuance. |
| Net Current Assets (Working Capital) | -£854,617 | -£3,769,110 | +£1,896,028 | Negative working capital – short-term liabilities exceed short-term assets by a large margin. |
| Annual Loss | -£6,173,755 | -£13,958,267 | (profit in 2023) | Losses narrowing – the bleeding is slowing, but the company is still deeply unprofitable. |
| Employee Count | 44 | 110 | n/a | Drastic cost cutting – headcount reduced by 60% in one year. |
| Share Capital Raised | £9,091,655 | £6,410,824 | n/a | Heavy reliance on equity injections – the company is being kept alive by investor cash. |
Other notable signs: - Total liabilities (£5.9M) are greater than total assets (£5.1M) – the company owes more than it owns. - Accumulated losses (P&L reserve) stand at -£77 million – a massive hole that would take years of profitability to fill. - Debt facility – a revolving credit facility of up to £7M from the principal shareholder is the main source of working capital, with £3.7M drawn at year-end.
3. Diagnosis: Chronic Financial Distress with Signs of Stabilisation
Primary condition: Severe negative equity and accumulated losses.
The company has a net liability position (negative equity) of nearly £800k, and its total shareholders' funds are deeply negative at -£77M. This is a classic symptom of a business that has been burning cash for years without generating sustainable profits. The company is technically insolvent on a balance sheet basis – it would not be able to meet all its liabilities if called upon to do so without external support.
Secondary condition: Negative working capital.
Current liabilities exceed current assets by £855k, meaning the company cannot pay all its short-term debts from its current resources. This is a liquidity risk, though mitigated by the shareholder credit facility.
Stabilising factors (the “improving vital signs”): - Cash has jumped from £177k to £1.14M – a healthy transfusion from the equity raise. - Losses have more than halved from £14M to £6.2M – the cost-cutting (headcount down 60%) is having an effect. - The company has a clear plan: a shareholder-led fundraising round expected in Q4 2026, plus a proposed acquisition. - The shareholder has provided a formal letter of support and increased the credit facility to £7M.
Risk factors: - The company is entirely dependent on the continued support of its principal shareholder and the success of the planned fundraising. If either fails, the business would likely be unable to continue as a going concern. - The proposed acquisition (mentioned in the accounts) adds execution risk – integrating an acquisition while in a fragile financial state is challenging. - The huge accumulated losses mean that even if the company returns to profitability, it will take many years to rebuild equity.
4. Recommendations: Specific Actions to Improve Financial Wellness
-
Complete the planned fundraising round as a matter of urgency.
- The Q4 2026 timeline must be met. Any delay could exhaust the increased credit facility and trigger a cash crisis.
- Consider securing a bridge facility in case the round slips. -
Continue aggressive cost rationalisation but protect core revenue-generating capabilities.
- The headcount reduction has helped, but ensure that further cuts do not damage the company’s ability to deliver to its defence and national security clients. -
Achieve positive operating cash flow as soon as possible.
- The company must move from burning cash to generating cash from operations. Focus on high-margin, recurring revenue contracts.
- Tighten debtor collection – debtors of £3.9M are high relative to cash; accelerate cash conversion. -
Negotiate longer payment terms with creditors or convert some debt into equity.
- The current liabilities are large. If possible, extend payment terms with suppliers or convert some shareholder loans into equity to improve the balance sheet. -
Develop a clear path to profitability with measurable milestones.
- The board should set a target date for breakeven (e.g., within 12 months) and monitor progress monthly.
- The proposed acquisition should be carefully evaluated – it must be accretive to cash flow and not add further financial strain. -
Consider a debt restructuring or equity conversion to eliminate negative net worth.
- Even after the fundraising, the company will still have a massive deficit. A debt-for-equity swap could clean up the balance sheet and restore positive net assets, which would improve confidence with banks and suppliers.
Executive Summary